LKT Labs

Biochemicals for Life Science Research

Dacomitinib Monohydrate

Dacomitinib Monohydrate

Product ID D0006
Cas No. 1042385-75-0
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $82.70 In stock
5 mg $159.90 In stock
25 mg $424.50 In stock
Bulk Quote

Quicklinks

Description

Dacomitinib is an ATP-competitive, irreversible pan-erbB receptor (EGFR) inhibitor that shows anticancer chemotherapeutic activity in models of squamous cell carcinoma, ovarian carcinoma, and non-small-cell lung cancer (NSCLC). Dacomitinib covalently modifies cytosine residues in the catalytic domain of this kinase, preventing phosphorylation of downstream targets such as Akt, and ERK, resulting in cell cycle arrest at the G0/G1 phase and induction of apoptosis. This compound also inhibits mutant EGF receptors in drug-resistant in vivo tumor models.

Product Info

Cas No.

1042385-75-0
Purity

≥99%
Formula

C24H25ClFN5O2 • H2O
Formula Wt.

487.95
IUPAC Name

(E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4- piperidin-1-ylbut-2-enamide;hydrate
Synonym

PF-00299804
Solubility

Soluble in water (<1 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), DMSO (19 mg/ml at 25 °C), and 1% DMSO/30% polyethylene glycol/1% Tween 80, pH 9 (10 mg/ml at 25 °C).
Appearance

off-white powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D0006 MSDS PDF
Info Sheet

D0006 Info Sheet PDF

References

Kalous O, Conklin D, Desai AJ, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012 Sep;11(9):1978-87. PMID: 22761403.

Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008 Jul;7(7):1880-9. PMID: 18606718.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E7668

    Etretinate

    Aromatic retinoid; RAR, RXR agonist.
    ≥98%
  • U6855

    Urocortin, rat

    Endogenous peptide, involved in stress signaling; ...
    ≥95%
  • V3252

    Vinorelbine Ditartrate

    Semi-synthetic vinca alkaloid from Catharanthus; m...
    ≥98%
  • T3324

    Tigecycline

    Glycylcycline; protein synthesis inhibitor.
    ≥98%
  • C5972

    Corynoline

    Alkaloid compound originally found in Corydalis; A...
    ≥98%
  • X1854

    p-Xyleneselenocyanate

    Synthetic derivative of selenocyanate.
    ≥99%
  • I7457

    1-Isothiocyanato-6-(methylsulfinyl)-hexane

    Synthetic derivative of 6-methylsulfinyl-hexane io...
    ≥98%
  • C5600

    CO-1686

    EGFR (WT, T790M) inhibitor.
    ≥98%
  • E5210

    Endomorphin-1

    Endogenous opioid peptide; μOr agonist.
    ≥95%
  • E5216

    β-Endorphin, camel

    Endogenous opioid peptide; μOR agonist.
    ≥95%
  • K1653

    Kendomycin

    Macrolide; ET antagonist, proteasome inhibitor.
    ≥98%
  • R2815

    Recombinant HIV-1 “0” group consensus

    Recombinant HIV-1 antigen fragment.
    ≥95%
  • S0930

    Schisantherin A

    Dibenzocyclooctadiene found in Schisandra.
    ≥98%
  • D183745

    Destruxin B

    Destruxin B, a cyclic depsipeptide, is a secondary...
    ≥96%
  • M4452

    MLN2480

    Raf inhibitor.
    ≥98%
  • V0146

    Valsartan

    AT1 inhibitor.
    ≥98%
  • A1319

    Adenosine Triphosphate Disodium Hydrate

    Endogenous coenzyme, unit of cellular energy, requ...
    ≥95%
  • D183744

    Destruxin A

    Destruxin A, a cyclic depsipeptide, is a secondary...
    ≥98%
  • G4484

    Glucagon-like Peptide II, rat

    Endogenous peptide hormone, involved in intestinal...
    ≥95%
  • G1646

    Geldanamycin

    HSP90 inhibitor.
    ≥97%